ARQ 197 clinical trials
Also written ARQ 197 and Tivantinib.
How each study uses ARQ 197 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
44 studies that test it; most in 2012 (13)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 5 |
| 2009 | 4 |
| 2010 | 7 |
| 2011 | 5 |
| 2012 | 13 |
| 2013 | 3 |
| 2014 | 2 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 31 · Other 14
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) (15) · National Cancer Institute (NCI) (10) · Daiichi Sankyo (8) · Kyowa Kirin Co., Ltd. (8) · Armando Santoro, MD (2) · SCRI Development Innovations, LLC (1) · Istituto Oncologico Veneto IRCCS (1)
Often tested with
Tested in the same studies.
Therapeutic Procedure (3) · Complementary or Alternative Medical Procedure (3) · Omeprazole (1) · (S)-warfarin (1) · Caffeine (1) · Digoxin (1) · Midazolam (1) · Folfox protocol (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses ARQ 197 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 45
- TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES)TerminatedPhase 2Istituto Oncologico Veneto IRCCSNCT02608411Written as ARQ197
- Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High SubjectsCompletedPhase 2Armando Santoro, MDNCT01892527Written as Tivantinib (ARQ197)
- Pazopanib and ARQ 197 for Advanced Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT01468922Written as ARQ 197
- ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal CancerCompletedPhase 1/2Daiichi SankyoNCT01075048Written as Tivantinib
- Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior TherapyCompletedPhase 3Daiichi SankyoNCT01755767Written as Tivantinib
- Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung CancerTerminatedPhase 3Daiichi SankyoNCT01244191Written as Tivantinib
- ARQ 197 for Participants With Relapsed or Refractory Germ Cell TumorsTerminatedPhase 2Daiichi SankyoNCT01055067Written as Tivantinib (ARQ 197)
- An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) ProtocolsCompletedPhase 1/2ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)NCT01178411Written as Tivantinib
- Study of the Combination of Tivantinib Plus Pemetrexed and CarboplatinCompletedPhase 1/2Armando Santoro, MDNCT02049060Written as Tivantinib
- Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple MyelomaCompletedPhase 2National Cancer Institute (NCI)NCT01447914Written as Tivantinib
- Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid TumorsCompletedPhase 1Daiichi SankyoNCT01149720Written as Tivantinib (ARQ 197) Capsule
- Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer SubjectsCompletedPhase 1Daiichi SankyoNCT01517399Written as tivantinib
- Effect of Tivantinib on the QTC Interval in Cancer SubjectsCompletedPhase 1Daiichi SankyoNCT01699061Written as Tivantinib
- Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic ImpairmentCompletedPhase 1Daiichi SankyoNCT02150733Written as Tivantinib
- Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by SurgeryCompletedPhase 2National Cancer Institute (NCI)NCT01688973Written as Tivantinib
- Tivantinib in Treating Patients With Metastatic Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT01519414Written as Tivantinib
- Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT01654965Written as Tivantinib
- Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung CancerCompletedPhase 2ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)NCT01395758Written as ARQ 197 plus erlotinib
- Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedPhase 1National Cancer Institute (NCI)NCT01749384Written as Tivantinib
- A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)CompletedPhase 3Kyowa Kirin Co., Ltd.NCT02029157Written as ARQ197
See all 45 studies that test ARQ 197 →
Given beside what is tested · 1 — ARQ 197 is usual care or a partner of the new treatment
Codes
What other systems call ARQ 197 · ClinicalTrials.gg INT005691
- UNII (FDA) PJ4H73IL17TIVANTINIBConfirmed FDA, Wikidata
- Wikidata Q72443796ARQ 197Confirmed FDA, Wikidata
- DrugBank DB12200One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | PJ4H73IL17 | TIVANTINIB | Confirmed FDA, Wikidata |
| Wikidata | Q72443796 | ARQ 197 | Confirmed FDA, Wikidata |
| DrugBank | DB12200 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.